Philly Pharmacy's Messy Logs End DEA Registration
Published Date: 7/14/2025
Notice
Summary
Just Here II Pharmacy in Philadelphia lost its DEA registration because it didn’t keep proper records of controlled substances, making it unsafe for the public. The pharmacy’s registration was suspended immediately and then officially revoked by the DEA, even though their registration expired at the end of 2024. This means Just Here II can no longer handle controlled drugs, protecting community safety.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Revokes Pharmacy Registration
Just Here II Pharmacy (DEA Certificate No. FJ1928689) had its DEA registration suspended on October 24, 2024 and the DEA issued a final order revoking the registration. The revocation bars the pharmacy from handling controlled substances and also denies any pending renewal, modification, or other registration applications for Just Here II in Pennsylvania; the Order is effective August 13, 2025.
Revocation Intended to Protect Public
If you live in Pennsylvania, the DEA found large discrepancies in Just Here II Pharmacy's controlled-substance records (for example: ~200 units of oxycodone 5 mg; ~1,459 units of oxycodone 15 mg; ~2,044 units of alprazolam 1 mg; ~2,930 units of alprazolam 2 mg; and ~2,839 units of promethazine with codeine) and revoked the registration to protect public health and safety. The DEA described variances for listed substances ranging from about 33% to 100% and made the revocation effective August 13, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-13121, JYA LLC d/b/a Webb's Square Pharmacy; Decision and Order
Webb's Square Pharmacy in Florida lost its DEA license because it gave out controlled medicines without proper prescriptions from July 2021 to March 2024. The pharmacy didn’t respond to the government’s warnings, so their registration was suspended and then revoked to protect public safety. This means they can’t legally handle controlled drugs anymore, effective immediately, impacting their business and customers.
Next: 2025-13125, Agency Information Collection Activities Under OMB Review
Heads up! The government is reviewing some paperwork rules to make sure they’re not too tricky or costly. If you’re a business or part of a group that fills out government forms, you might see some changes soon. This review helps keep things fair and saves time and money for everyone involved.